Similar to a previous report in a retrospective study of (standard dose) BRAF inhibition combined with MEK inhibition in patients with melanoma who had already received immunotherapy,39 the high rate of AEs observed in this study of encorafenib in combination with binimetinib for patients who had previously received anti-PD-1–based immunotherapy may have been partially due to the short time between their last immunotherapy dose and the beginning of their new treatment. This evidence concerns the gene MAP2K7 and melanoma.